Page 271 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 271
ICC intraclass correlation coefficient
IHP international harmonization project
IPD individual patient data
ITT intention-to-treat
IPI international prognostic index
I-PET interim positron emission tomography
IQR interquartile range
KM Kaplan-Meier
LDH lactate dehydrogenase
MBP mediastinal blood pool
MTV metabolic tumor volume
Mo months
MV majority vote
NA negative agreement
NCCN-IPI national comprehensive cancer network international
prognostic index NFT no further treatment
NHL non-Hodgkin lymphoma NK natural killer
NM nuclear medicine
NPV negative predictive value OA overall agreement
OS overall survival
PA positive agreement
PD progressive disease
PET positron emission tomography
PET/CT positron emission tomography and computed tomography PETRA PET Re-Analysis
PFS progression-free survival
PMBCL primary mediastinal B-cell lymphoma
PMD progressive metabolic disease
PMR progressive metabolic response
PPV positive predictive value
PTLD post-transplant lymphoproliferative disease
R-ACVBP rituximab, doxorubicin, vindesine, bleomycine, prednisone R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine,
List of Abbreviations
269
A
